Stopping GLP-1 Medications May Raise Heart Risk, New Study Finds New research reveals the cardiovascular benefits of GLP-1 drugs build slowly but erode quickly, with two years off the medication raising cardiac risk by as much as 22%
Cellular response to oxidative stress and ascorbic acid in melanoma cells overexpressing -glutamyltransferase
Every batch is independently tested for HPLC purity, mass-spec identity, and endotoxin levels
Notably, its role in ferroptosis is biphasic: while high, exogenously delivered concentrations of NO can induce this iron-dependent cell death, lower, endogenously regulated levels can be protective by terminating lipid peroxidation
While one might think adding a GLP-1 agonist would help, the primary effect of high-dose agonists is usually a further slowing of the upper GI tract